Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

BACKGROUND: Immune checkpoint inhibitors have revolutionized the treatment paradigm of highly lethal malignancies like advanced non-small cell lung cancer (NSCLC), demonstrating long-term tumour control and extended patient survival. Unfortunately, only 25–30% of patients experience a durable benefi...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Transl Med
Huvudupphovsmän: Botticelli, Andrea, Cerbelli, Bruna, Lionetto, Luana, Zizzari, Ilaria, Salati, Massimiliano, Pisano, Annalinda, Federica, Mazzuca, Simmaco, Maurizio, Nuti, Marianna, Marchetti, Paolo
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2018
Ämnen:
Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6080500/
https://ncbi.nlm.nih.gov/pubmed/30081936
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-018-1595-3
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk